PNPLA3对肝细胞和肝癌细胞脂质代谢的影响*

doi:10.3969/j.issn.1672-5069.2020.02.038

Abstract

Abstract: The PNPLA3 gene is expressed in both humans and mammals and is also expressed in liver cancer cells. PNPLA3 can cause accumulation of triglycerides in hepatocytes and fatty degeneration in hepatocytes after its mutation in humans and mice. Overexpression of mutant PNPLA3 in human and rat liver cancer cells also results in lipid accumulation in liver cancer cells compared to overexpression of its wild-type. In this paper, we summarize the effects of PNPLA3 gene on lipid metabolism in hepatocytes and hepatoma cells, and try to explain the effects of PNPLA3 on human hepatocytes and liver cancer cells, rat, mouse hepatocytes and liver cancer cells.

Key words: PNPLA3, Triglyceride, Hepatocytes, Hepatoma cells

Ning Baoshuo, Li Yiling. Effect of PNPLA3 on lipid metabolism of hepatocytes and hepatocellular carcinoma cells[J]. Journal of Practical Hepatology, 2020, 23(2): 300-304.

References

[1] Cohen JC, Horton JD, Hobbs HH.Human fatty liver disease: Old questions and new insights.Science,2011,332(6037):1519-1523.
[2] Day CP. Non-alcoholic fatty liver disease: a massive problem.Clin Med,2011,11(2):176-178.
[3] Bugianesi E, Moscatiello S,Ciaravella MF, et al. Insulin resistance in nonalcoholic fatty liver disease.Curr Pharm Des,2010,16(17):1941-1951.
[4] Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review.Gastroenterol Hepatol,2012,35(1):32-41.
[5] Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet, 2008,40(12):1461-1465.
[6] Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with Nonalcoholic fatty liver disease.J Biol Chem,2011,286(43):37085-37093.
[7] Kershaw EE, Hamm JK, Verhagen LAW, et al. Adipose triglyceride lipase: Function, regulation by insulin, and comparison with adiponutrin. Diabetes,2006,55(1):148.
[8] Romeo S, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-Iike phospholipase domain-containing 3 protein.Curr Opin Lipidol,2010,21(3):247-252.
[9] Raewhitcombe SM, Kennedy D, Voyles M, et al. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.Biochem Biophys Res Commun,2010,402(4):767-772.
[10] Baulande S, Lasnier F, Lucas M, et al. Adiponutrin, a transmembrane protein corresponding to a novel dietary and obesity linked mRNA specifically expressed in the adipose lineage. J Biol Chem,2001,276(36):33336.
[11] Polson DA, Thompson MP. Adiponutrin mRNA expression in white adipose tissue is rapidly induced by meal-feeding a high-sucrose diet. Biochem Biophys Res Commun,2003,301(2):261-266.
[12] Polson DA, Thompson MP. Macronutrient composition of the diet differentially affects leptin and adiponutrin mRNA expression in response to meal feeding.J Nutr Biochem,2004,15(4):242-246.
[13] Li J, Yu X, Pan W, et al. Gene expression profile of rat adipose tissue at the onset of high fat diet obesity.Am J Physiol Endocrinol Metab,2002,282(6):E1334.
[14] Huang Y, Hobbs HH. A feed forward loop amplifies nutritional regulation of PNPLA3.Proc Natl Acad of Sci U S A,2010,107(17):7892-7897.
[15] Liu Y, Moldes M, Bastard JP, et al. Adiponutrin: A new gene regulated by energy balance in human adipose tissue.J Clin Endocrinol Metab, 2004, 89(6):2684-2689.
[16] Perttilä J, Huamansamanez C, Caron S, et al. PNPLA3 is regulated by glucose in humanhepatocytes, and its I148M mutant slows down triglyceride hydrolysis.Am J Physiol Endocrinol Metab,2012,302(9):E1063.
[17] Soni KG, Mardones GA, Sougrat R, et al. Coatomer-dependent protein delivery to lipid droplets.J Cell Sci,2009,122(11):1834-1841.
[18] He S, Mcphaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.J Biol Chem,2010,285(9):6706-6715.
[19] Victor RG, Haley RW, Willett DL, et al. Dallas heart study investigators. The Dallas heart study: a population based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health.Am J Cardiol,2004,93(12):1473-1480.
[20] Speliotes EK, Yergesarmstrong LM, Wu J, et al. Genome wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.Plos Genet,2011,7(3):E1001324.
[21] Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with nonalcoholic fatty liver disease.J Hepatol,2016,64(5):1167-1175.
[22] Smagris E, Basuray S, Li J, et al. Pnpla3 I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology,2015,61(1):108-118.
[23] Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.J Clin Invest,2012,122(11):4130-4144.
[24] 乔爱君. 小鼠PNPLA3基因影响机体糖脂代谢及FoxO1抑制SREBP-1c表达的分子机制研究.北京协和医学院(中国医学科学院);北京协和医学院;中国医学科学院;清华大学医学部,2011.
[25] Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin like phospholipase domain containing 3 on lipid induced hepatic steatosis and insulin resistance in rats.Hepatology,2013,57(5):1763-1772.
[26] Hoekstra M, Li ZJ, Van EM, et al. The expression level of non alcoholic fatty liver disease related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status.J Hepatol,2010,52(2):244-251.
[27] Basantani MK, Sitnick MT, Cai L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome.J Lipid Res,2011,52(2):318.
[28] Kollerits B, Coassin S, Beckmann ND, et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B containing lipoproteins.Hum Mol Genet,2015,18(23):4669-4676.
[29] Lake AC, Sun Y, Li JL, et al. Expression, regulation and triglyceride hydrolase activity of adiponutrin family members.J Lipid Res,2005,46(11):2477.
[30] Jenkins CM, Mancuso DJ, Yan W, et al. Identification, cloning, expression and purification of three novel human calcium independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem,2004,279(47):48968-48975.
[31] Zechner R, Strauss JG, Haemmerle G, et al. Lipolysis: pathway under construction.Curr Opin Lipidol,2005,16(3):333-340.
[32] Goran MI, Walker R, Allayee H. Genetic related and carbohydrate related factors affecting liver fat accumulation.Clin Nutr,2012,15(4):392.
[33] Davis JN, Lê KA, Walker RW, et al. Increased hepatic fat in overweight hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption.Am.J Clin Nutr,2010,92(6):1522-1527.
[34] Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin like phospholipase 3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology,2010,51(4):1209-1217.
[35] Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Atherosclerosis,2011,12(1):13.
[36] Chan DC, Watts GF, Gan SK, et al. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very low density lipoprotein apolipoprotein B100 in obesity.Arterioscler.Thromb Vasc Biol,2010,30(5):1043.
[37] Pirazzi C, Adiels M, Burza MA, et al. Patatin like phospholipase domain containing 3 ( PNPLA3 ) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.J Hepatol,2012,57(6):1276-1282.
[38] Kumari, Manju, Schoiswohl, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.Cell Metab,2012,15(5):691-702.
[39] Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes.J Hepatol,2011,55(1):145-153.
[40] Ruhanen H, Perttilä J, Hölttä-Vuori M, et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling.J Lipid Res,2014,55(4):739-746.
[41] Green CJ, Johnson D, Amin HD, et al. Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.Am J Physiol Endocrinol Metab,2015,309(6):E511-E522.
[42] Pirazzi C, Adiels M, Burza MA, et al. Patatin like phospholipase domain containing 3 ( PNPLA3 ) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol,2012,57(6):1276-1282.
[43] Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.J Clin Invest,2012,122(11):4130-4144.
[44] Smagris E, Basuray S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis.Hepatology,2015,61(1):108-118.
[45] Hao L, Ito K, Huang KH, et al. Shifts in dietary carbohydrate lipid exposure regulate expression of the nonalcoholic fatty liver disease associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.Metabolism,2014,63(10):1352-1362.
[46] Kershaw EE, Hamm JK, Verhagen LAW, et al. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin.Diabetes,2006,55(1):148.

Effect of PNPLA3 on lipid metabolism of hepatocytes and hepatocellular carcinoma cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	Ren Guoliang, Li Liansheng, Liu Gang, et al. Improvement of insulin resistance, lipid profile and oxidative stress index by calorie restriction diet in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 219-222.
[2]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[3]	Guo Liping, Zhang Chenghong, Ning Baoshuo, et al.. An improved approach for seperating hepatocytes from neonatal rats in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 17-20.
[4]	Xu Jian, Lu Xiangyu, Gong Jun, et al.. Prevalence of metabolic syndrome and new-onset cholelithiasis in the elderly [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 133-136.
[5]	Li Junfeng, Zheng Sujun, Liu Shuang, et al.. Impact of UGCG siRNA on 7702 hepatocyte proliferation in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 697-700.
[6]	Tian Junwei, Xiao Yuanli, Wang Yanchao.. Diagnostic value of serum TG/HDL-C ratio in patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 416-419.
[7]	Zhu Chanyan,Qu Jichen,Cao Haixia,et al.. Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 288-291.
[8]	Cui Dan,Yang Baoshan. Role of Nrf2 in the regulation of hepatocyte apoptosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 365-368.
[9]	Tian Li, Yin Ling, Guan Lili, et al.. Inhibitory effect of salidroside on cytochrome P4502E1 protein expression in primary-cultured rat hepatocytes with steatosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 270-273.
[10]	Zhao Fei, Xie Ping, Jiang Jiali. Tamoxifen promotes lipid accumulation in HepG2 cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 30-33.